Breast cancers that do not express these receptors (as well as the Progesterone receptor (PR)) are termed “triple negative breast cancers” (TNBCs) and have the poorest clinical outcome, reflecting, in part, the fact that they lack targeted therapies. This evidence concerns the gene PGR and breast cancer.